N-4-fluorophenyl N'-cyclohexyl urea | 200058-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-4-fluorophenyl N'-cyclohexyl urea
• 英文别名: 1-Cyclohexyl-3-(4-fluorophenyl)urea
• CAS: 200058-85-1
• 化学式: C₁₃H₁₇FN₂O
• mdl: MFCD00029496
• 分子量: 236.289
• InChiKey: AFUBYKNBJKFZMM-UHFFFAOYSA-N

物化性质

• 熔点：
  104.4 °C
• 沸点：
  332.4±34.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-4-fluorophenyl N'-cyclohexyl urea 在 四(三苯基膦)钯 、 三乙胺 、 三苯基膦 、 二溴三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 13.0h， 生成 [3-Cyclohexyl-4-vinyl-oxazolidin-(2Z)-ylidene]-(4-fluoro-phenyl)-amine
  参考文献：
  名称：

  Highly Enantioselective Synthesis of 1,3-Oxazolidin-2-imine Derivatives by Asymmetric Cycloaddition Reactions of Vinyloxiranes with Unsymmetrical Carbodiimides Catalyzed by Palladium(0) Complexes

  摘要：

  4-Vinyl-1,3-oxazoilidin-2-imine derivatives have been synthesized by cycloaddition reactions of 2-vinyloxiranes with unsymmetrical carbodiimides catalyzed by palladium(0) complexes-in excellent total isolated yields. After reaction two compounds were always formed, one of which was isolated as the major product. A bulky alkyl group on one of the nitrogen atoms of the carbodiimide enhanced the product ratio in favor of the N-aryl-3-alkyl-1,3-oxazolidin-2-imine. Highly enantioselective cycloadducts (up to >99% ee) were formed by using TolBINAP as the chiral phosphine ligand, in THF at ambient temperatures. The enantiodetermination is believed to be dependent on nucleophilic attack of the anionic nitrogen of the carbodiimide due to the steric interaction of the carbodiimide substituents with the chiral phosphine ligand.

  DOI：

  10.1021/jo9804341
• 作为产物：
  描述：

  4-氟苯胺 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-4-fluorophenyl N'-cyclohexyl urea
  参考文献：
  名称：

  4-[18F]fluorophenyl ureas via carbamate-4-nitrophenyl esters and 4-[18F]fluoroaniline

  摘要：

  合成了四种不同的无载体添加（n.c.a.）4-[18F]氟苯基尿酸酯衍生物作为模型化合物，采用了两种不同的合成路径。在这两种情况下，碳酸酯-4-硝基苯酯被用作中间体。无载体添加的4-[18F]氟苯胺与几种胺的碳酸酯反应，或者先形成无载体添加的4-[18F]氟苯胺的碳酸酯，再随后添加胺以生成尿酸酯衍生物。选择适当的反应路径取决于前体合成的可能性。 合成时间为50分钟时，放射化学产率可达80%，而未检测到放射化学副产物。这些高产率的获得归功于优化的无载体添加4-[18F]氟苯胺的制备，其放射化学产率高达90%。在多种放射合成方式中，选择了在二硝基苯上用无载体[18F]氟化物进行取代，并采用磷酸和黑色铂进行第二个硝基的还原。 版权所有 © 2006 John Wiley & Sons, Ltd.

  DOI：

  10.1002/jlcr.1121

文献信息

• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• Structural refinement of inhibitors of urea-based soluble epoxide hydrolases
  作者：Christophe Morisseau、Marvin H. Goodrow、John W. Newman、Craig E. Wheelock、Deanna L. Dowdy、Bruce D. Hammock

  DOI：10.1016/s0006-2952(02)00952-8

  日期：2002.5

  The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties. (C) 2002 Published by Elsevier Science Inc.
• IMMUNOREGULATORY AGENTS
  申请人：Flexus Biosciences, Inc.

  公开号：EP3215142B1

  公开（公告）日：2021-03-24
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION
  申请人：Kroetz Deanna L.

  公开号：US20110245331A1

  公开（公告）日：2011-10-06

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.
• US8815951B2
  申请人：——

  公开号：US8815951B2

  公开（公告）日：2014-08-26